Glycogene Engineering Service

Glycogene Engineering Service

Strive to Create Quality Services

CD BioGlyco is committed to building a leading glycogene engineering service. To this end, we specialize in building highly executive and experienced research teams. We have a wide variety of Technologies for Gene Editing. We regulate the expression of glycogene through overexpression, knockdown, knock-in, knockdown, and many other Strategies. Based on our vast experience, we achieve one-stop technical service solutions for gene editing, bioinformatics, pharmacology, efficacy, etc.

One-stop glycogene editing service.Fig.1 One-stop glycogene editing service. (CD BioGlyco)

  • Glycogene Editing Service
    Glycosylation is a common post-translational modification that occurs in the Golgi apparatus and endoplasmic reticulum. The process is coordinately regulated by glycogenes such as glycosyltransferases, glycosidases, nucleotide sugar synthesis, and transport, etc. Glycogene is a group of genes encoding glycosyltransferases, glycosidases, and other glycan-related genes. Our glycogene editing service is aimed at research partners in various fields such as animal, plant, and microbiology. Glycosylation plays important functions in cells and organisms. It is involved in regulating important biological processes such as cell recognition, adhesion, and signal transduction. Abnormal glycosylation leads to inflammation, tumors, and other diseases. We are committed to influencing the glycosylation process by regulating the expression of glycogene. We also analyze the correlation between various glycosyltransferases, glycosidases, etc., and the occurrence of diseases. We aim to find new targets for disease treatment. We also expand the application of glycosyltransferases, glycosidases, etc., by heterologous expression of target proteins with functional properties.
  • Technologies for Gene Editing
    We have mature technologies for gene editing, including transcription activator-like effector nucleases (TALEN) technology, CRISPR/Cas9 technology, zinc-finger nucleases (ZFN) technology, etc. We use technologies for gene editing to produce cell lines, animal models, and many other expression systems. Our services include metabolic engineering modifications, apoptosis regulation, inhibition of cancer cell migration, and many other types of services.

Advantages for gene editing.Fig.2 Advantages for gene editing. (CD BioGlyco)

Glucosyltransferase Engineering Service

Glucosyltransferase catalyzes the transfer of glucose from specifically activated donors to specific acceptor molecules. It is a highly diverse group of enzymes. CD BioGlyco affects sugar synthesis by knocking out or overexpressing the glucosyltransferase gene.

Galactosyltransferase Engineering Service

Galactosyltransferase belongs to the family of glycosyltransferases, which is classified into B3galts, B4galts, etc. CD BioGlyco has extensive experience in galactosyltransferase gene modification in animals, plants, and microorganisms.

Mannosyltransferase (MTase) Engineering Service

MTase is commonly found in eukaryotes. It affects plant disease resistance and immunity, embryo development, protein glycosylation, cancer cell migration, etc. CD BioGlyco will modify different MT genes according to customers' requirements. We also provide MT heterologous expression service.

N-Acetylglucosaminyltransferase (GnT) Engineering Service

GnTs catalyze the synthesis of complex glycans with multiple structures. It has an important role in glycoprotein synthesis. CD BioGlyco investigates the effects of GnT gene modification by constructing various mouse and cell line models.

N-Acetylgalactosaminyltransferase (GALNT) Engineering Service

Polypeptide GALNT is an initiating enzyme that catalyzes the modification of mucin-type O-glycosylation. It affects tumor cell genesis, proliferation, and migration, etc. CD BioGlyco offers a wide range of GALNT gene modification services to help clients investigate its application in disease treatment.

Fucosyltransferase (FucT) Engineering Service

FucT is highly expressed in tumors such as lung cancer and colon cancer. It is associated with various diseases such as atherosclerosis, etc. CD BioGlyco will help clients study the application of FUT3, FUT4, FUT7, and other genes in the treatment of diseases according to their requirements.

Sialyltransferase (ST) Engineering Service

ST is an enzyme required for the synthesis of sialylated oligosaccharides. CD BioGlyco provides services such as ST gene editing, enzyme activity assay, mouse disease modeling, and compound testing.

Glucuronyltransferase Engineering Service

UDP-glucuronyltransferase (UGT) is a microsomal glycosyltransferase that is associated with a variety of diseases. Its encoding gene, UGT, is a supergene family that encodes several isoenzymes. CD BioGlyco edits multiple UGT genes to validate UGT function and applications in drug metabolism.

GAG Polymerase Engineering Service

The Gag gene encodes a protein that produces many HIV-1 CTL antigenic epitopes. The polymerase gene encodes an enzyme that produces reverse transcriptase and protease enzymes, among others. CD BioGlyco provides HIV vaccine development and retroviral packaging services.

Sulfotransferase (SULT) Engineering Service

SULT is a highly conserved class of proteins. It catalyzes the sulphonation of a range of compounds. CD BioGlyco provides gene editing services for SULT of human origin and plant SULT.


  • Validation of the functions of various glycosyltransferases in plants, microorganisms, etc.
  • Synthesis of glycosyltransferases with specific functions.
  • Study of the application of glycosyltransferases in the treatment of diseases.


  • Our technical team has rich experience in gene editing and provides complete technical solutions for CRISPR gene editing projects.
  • We edit a rich variety of glycogene, with a high success rate of gene editing, a short experimental period, and other advantages.
  • The technologies for glycogene editing help to find new therapeutic targets or disease markers for disease treatment.

CD BioGlyco provides high-quality glycogene engineering transformation services for biological research enterprises, scientific research institutes, etc. In addition, we also provide a Cancer Glycogene Discovery Service. Please feel free to contact us with any questions.


  1. Kelkar, A.; et al. Forward genetic screens of human glycosylation pathways using the glycogene CRISPR library. Curr Protoc. 2022, 2(4): e402.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.